Board change
26 Enero 2010 - 4:00AM
UK Regulatory
TIDMCRYO
RNS Number : 1218G
Cryo-Save Group NV
26 January 2010
26 January 2010
Cryo-Save Group N.V.
Board change
Cryo-Save Group N.V. (AIM/Euronext: CRYO, "Cryo-Save" or "the Group"), Europe's
leading stem cell bank, announces that Werner Spinner, a non-executive
director, has resigned from the Board with immediate effect. Cryo-Save will look
for a successor to join its two other non-executive directors.
Marc Waeterschoot, Chief Executive, commented:
"I would like to thank Werner for his services over the past years, which have
contributed to the successful execution of the Group's development. On behalf of
the Board, we wish him well for the future and with his numerous other roles."
+-------------------------------------+----------------------------------+
| For further details: | |
+-------------------------------------+----------------------------------+
| | |
+-------------------------------------+----------------------------------+
| Cryo-Save Group | + 31 (0) 575 548 998 |
+-------------------------------------+----------------------------------+
| Marc Waeterschoot, Chief Executive | |
| Arnoud van Tulder, Chief Financial | |
| Officer | |
+-------------------------------------+----------------------------------+
| | |
+-------------------------------------+----------------------------------+
| Daniel Stewart & Company plc | + 44 (0) 20 7776 6550 |
+-------------------------------------+----------------------------------+
| Simon Leathers / Emma Earl | |
+-------------------------------------+----------------------------------+
| | |
+-------------------------------------+----------------------------------+
| College Hill | + 44 (0) 20 7457 2020 |
+-------------------------------------+----------------------------------+
| Adrian Duffield/Rozi Morris | |
+-------------------------------------+----------------------------------+
About Cryo-Save
With more than 120,000 samples saved, Cryo-Save is the leading stem cell bank in
Europe and one of the fastest growing in the world. Driven by its international
business strategy, Cryo-Save is now represented in 38 countries on three
continents and has state-of-the-art processing facilities in Belgium, Germany,
Dubai, India and France (under construction).
Cryo-Save sets the highest quality standards in stem cell storage, as it aims to
make an important contribution to conquer possible life-threatening diseases in
the future. As a service to the public, Cryo-Save offers a Cost-free Family
Donation Programme, free of charge, to families wishing to store their newborn's
umbilical cord blood stem cells for a family member diagnosed with a
life-threatening disease treatable by stem cells. The company is committed to
further improve stem cell cryopreservation techniques, by participating in
European Commission funded projects, in Universities and Hospitals.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOABFMLTMBBTMLM
Cryo-Save (LSE:CRYO)
Gráfica de Acción Histórica
De Feb 2025 a Mar 2025
Cryo-Save (LSE:CRYO)
Gráfica de Acción Histórica
De Mar 2024 a Mar 2025
Real-Time news about Cryo-Save (London Stock Exchange): 0 recent articles
Más de Cryo-Save Artículos de Noticias